{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:10:39Z","timestamp":1790327439874,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hrthm.2026.03.1958","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:27:30Z","timestamp":1775575650000},"page":"e2601-e2612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct mechanistic features of atrial fibrillation in hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-7686","authenticated-orcid":false,"given":"Michael","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-0202","authenticated-orcid":false,"given":"Marco V.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.03.1958_bib1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/STROKEAHA.121.034213","article-title":"Ischemic stroke in patients with hypertrophic cardiomyopathy according to presence or absence of atrial fibrillation","volume":"53","author":"Fauchier","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib3","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMra2413445","article-title":"Hypertrophic cardiomyopathy","volume":"393","author":"Braunwald","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.123.065037","article-title":"Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy","volume":"148","author":"Rowin","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.hroo.2023.01.002","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: a proportional meta-analysis and systematic review of single-arm studies","volume":"4","author":"Latif","year":"2023","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43856-023-00315-8","article-title":"Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy","volume":"3","author":"Chen","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.amjcard.2019.04.028","article-title":"Meta-analysis of atrial fibrillation in patients with various cardiomyopathies","volume":"124","author":"Noubiap","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021970","article-title":"Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data","volume":"10","author":"Buckley","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.tcm.2025.01.007","article-title":"Atrial fibrillation burden and management in cardiomyopathies: current evidence and unmet needs","volume":"35","author":"Antonopoulos","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jce.15304","article-title":"Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy","volume":"33","author":"Sridharan","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib12","doi-asserted-by":"crossref","first-page":"H568","DOI":"10.1152\/ajpheart.00252.2023","article-title":"Fine tuning contractility: atrial sarcomere function in health and disease","volume":"326","author":"Burnham","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/2047487319828474","article-title":"Risk factors for atrial fibrillation in hypertrophic cardiomyopathy","volume":"28","author":"Philipson","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib14","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.hrthm.2023.09.016","article-title":"Treatment for atrial fibrillation in hypertrophic cardiomyopathy: welcome back ablate and pace","volume":"20","author":"Nademanee","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.hrthm.2025.05.021","article-title":"Ablation of atrial fibrillation and risk of stroke: a meta-analysis","volume":"23","author":"Providencia","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/CIRCULATIONAHA.115.015085","article-title":"Management of atrial fibrillation in hypertrophic cardiomyopathy","volume":"133","author":"MacIntyre","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib18","first-page":"876","article-title":"From atrial fibrillation management to atrial myopathy assessment: the evolving concept of left atrium disease in hypertrophic cardiomyopathy","volume":"40","author":"Fumagalli","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib19","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: is the extent of septal hypertrophy important?","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/joa3.13061","article-title":"Clinical and pathophysiologic determinants of catheter ablation outcome in hypertrophic cardiomyopathy with atrial fibrillation","volume":"40","author":"Lee","year":"2024","journal-title":"J Arrhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jacep.2018.10.016","article-title":"Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging","volume":"5","author":"Sivalokanathan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib22","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1016\/j.hrthm.2025.08.008","article-title":"Left atrial late gadolinium enhancement and atrial fibrillation in hypertrophic cardiomyopathy","volume":"22","author":"Garbin","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2021.07.030","article-title":"Clinical utility of cardiac magnetic resonance imaging to assess the left atrium before catheter ablation for atrial fibrillation - A systematic review and meta-analysis","volume":"339","author":"Ghafouri","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcmg.2011.08.020","article-title":"CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy","volume":"5","author":"Rowin","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/CIRCIMAGING.112.000333","article-title":"T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914845","article-title":"Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts","volume":"24","author":"Schlittler","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib29","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/cells10102789","article-title":"Ion channel impairment and myofilament Ca2+ sensitization: two parallel mechanisms underlying arrhythmogenesis in hypertrophic cardiomyopathy","volume":"10","author":"Santini","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib30","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/cvr\/cvaa124","article-title":"Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy","volume":"116","author":"Coppini","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.yjmcc.2022.08.361","article-title":"Remodelling of potassium currents underlies arrhythmic action potential prolongation under beta-adrenergic stimulation in hypertrophic cardiomyopathy","volume":"172","author":"Doste","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib32","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050407","article-title":"Reduced connexin-43 expression, slow conduction and repolarisation dispersion in a model of hypertrophic cardiomyopathy","volume":"17","author":"Lim","year":"2024","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1305485","article-title":"Catheter ablation in patients with atrial fibrillation and dilated cardiomyopathy","volume":"11","author":"Siow","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/jcm13020501","article-title":"Atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac amyloidosis: from clinical management to catheter ablation indication","volume":"13","author":"Mistrulli","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib36","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib37","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib39","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1007\/s00018-021-03971-y","article-title":"Alpha and beta myosin isoforms and human atrial and ventricular contraction","volume":"78","author":"Walklate","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12947-020-00233-y","article-title":"Contribution of sarcomere gene mutations to left atrial function in patients with hypertrophic cardiomyopathy","volume":"19","author":"Chung","year":"2021","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00330-023-10128-x","article-title":"Association between left atrial myopathy and sarcomere mutation in patients with hypertrophic cardiomyopathy: insights into left atrial strain by MRI feature tracking","volume":"34","author":"Wang","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib42","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.3390\/ijms22136941","article-title":"Electrophysiological and structural remodeling of the atria in a mouse model of troponin-I mutation linked hypertrophic cardiomyopathy: implications for atrial fibrillation","volume":"22","author":"Lim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ng.781","article-title":"A rare variant in MYH6 is associated with high risk of sick sinus syndrome","volume":"43","author":"Holm","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib44","doi-asserted-by":"crossref","first-page":"615A","DOI":"10.1016\/j.bpj.2024.11.3175","article-title":"BPS2025 - Functional assessment of recombinant human alpha-cardiac myosin and the effect of atrial arrhythmia mutations","volume":"124","author":"Pawar","year":"2025","journal-title":"Biophys J"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/eurheartj\/ehw379","article-title":"A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation","volume":"38","author":"Gudbjartsson","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11303","article-title":"A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation","volume":"7","author":"Orr","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib47","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.864547","article-title":"Genotype-driven pathogenesis of atrial fibrillation in hypertrophic cardiomyopathy: the case of different TNNT2 mutations","volume":"13","author":"Pioner","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005191","article-title":"Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy","volume":"11","author":"Lee","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib50","article-title":"Clinical and genetic risk factors predict atrial fibrillation on the basis of hypertrophic cardiomyopathy","volume":"14","author":"Lee","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/qjmed\/hcu046","article-title":"Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"107","author":"Orenes-Pi\u00f1ero","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy","volume":"3","author":"Weissler-Snir","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100899","article-title":"Transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Pierri","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100900","article-title":"Atrial fibrillation in patients with hypertrophic cardiomyopathy: Caveat Ablator","volume":"3","author":"Marine","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-022-02713-6","article-title":"Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis","volume":"55","author":"Ye","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib58","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.hrthm.2025.05.046","article-title":"External validation of atrial fibrillation risk prediction tools in a racially diverse cohort of patients with hypertrophic cardiomyopathy","volume":"22","author":"Pronovost","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib59","article-title":"Predictive value of sudden cardiac death risk stratification for outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy","author":"Du","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib60","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2023.05.021","article-title":"Risk of left atrial thrombus in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"82","author":"Burczak","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10840-023-01642-5","article-title":"Persistence of left atrial thrombus in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"67","author":"Burczak","year":"2024","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib63","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.hrthm.2025.07.010","article-title":"Utility of transesophageal echocardiography prior to cardioversion in patients with atrial fibrillation and hypertrophic cardiomyopathy","volume":"23","author":"Ibrahim","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib64","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.hrthm.2024.05.038","article-title":"Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation","volume":"21","author":"Aglan","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib65","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.hrthm.2023.02.002","article-title":"Very long term outcomes of atrial fibrillation ablation","volume":"20","author":"Winkle","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib66","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib68","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.05.049","article-title":"Outcomes of concomitant surgical ablation in patients undergoing surgical myectomy for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis","volume":"387","author":"Kharbanda","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib70","first-page":"72","article-title":"Rhythm control better prevents stroke than rate control in patients with concomitant hypertrophic cardiomyopathy and atrial fibrillation: a nationwide population based cohort study with long-term follow-up","volume":"41","author":"Wu","year":"2025","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib72","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","article-title":"Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy","volume":"123","author":"Miller","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib73","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037639","article-title":"Disopyramide revisited for treatment of symptomatic obstructive hypertrophic cardiomyopathy: efficacy and safety in patients treated for at least 5 years","volume":"14","author":"Massera","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib74","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3390\/jcm12072725","article-title":"Real-world use and predictors of response to disopyramide in patients with obstructive hypertrophic cardiomyopathy","volume":"12","author":"Maurizi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib75","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib76","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/pace.12227","article-title":"Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy","volume":"36","author":"Barajas-Mart\u00ednez","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib78","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib79","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2022.10.014","article-title":"Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center","volume":"370","author":"Argir\u00f2","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (ranolazine in atrial fibrillation following an electrical cardioversion) study","volume":"12","author":"De Ferrari","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/europace\/euu217","article-title":"Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial","volume":"17","author":"Scirica","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104521","article-title":"The role of amiodarone in contemporary management of complex cardiac arrhythmias","volume":"151","author":"Mujovi\u0107","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib83","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: A Scientific Statement From the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib84","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib85","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib86","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","article-title":"Atrial fibrillation in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: real-world incidence, management, and outcomes","volume":"11","author":"Boyle","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2026.02.035","article-title":"Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: a multicenter study","author":"Nguyen","year":"2026","journal-title":"J Card Fail"},{"issue":"suppl 1","key":"10.1016\/j.hrthm.2026.03.1958_bib89","article-title":"Abstract 4143175: Real-world long-term effectiveness of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: a multicenter observational study (MARVEL-HCM)","volume":"150","author":"Abraham","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.hrthm.2025.08.031","article-title":"Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: an analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials","volume":"23","author":"Rowin","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133846","article-title":"Short-term incidence and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy receiving cardiac myosin inhibitors: a systematic review and meta-analysis","volume":"442","author":"Shawki","year":"2026","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib93","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib94","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.hrthm.2024.11.041","article-title":"Managing drug-drug interactions with mavacamten: a focus on combined use of antiarrhythmic drugs and anticoagulants","volume":"22","author":"Ricci","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/jcdd12040114","article-title":"The role of cardiac magnetic resonance in characterizing atrial cardiomyopathy and guiding substrate ablation in atrial fibrillation: a narrative review","volume":"12","author":"Jabbour","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib96","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1001\/jama.2022.8831","article-title":"Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the DECAAF II randomized clinical trial","volume":"327","author":"Marrouche","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.hrthm.2026.03.1958_bib97","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008707","article-title":"Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial","volume":"13","author":"Bisbal","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:40:06Z","timestamp":1790325606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126022411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1547527126022411"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.03.1958","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct mechanistic features of atrial fibrillation in hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.03.1958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}